tation Alemtuzumab (Campath s ) is a humanized monoclonal antibody that targets the CD52 antigen, which is expressed abundantly on the surface of normal and malignant lymphocytes, 1 but not on hematopoietic stem cells. 2 Administration of alemtuzumab results in rapid clearance of circulating normal and malignant T and B lymphocytes via a number of host effector mechanisms, including complement fixation and antibody-dependent cell-mediated cytotoxicity. 3 Alemtuzumab is highly effective as a therapy for mature T-or B-cell lymphoproliferative disorders. When given as treatment for refractory B-cell chronic lymphocytic leukemia (CLL), the overall response (OR) rates are 33-40%, 4, 5 while, in untreated patients, the OR rates are 87-89%. 6, 7 In B-cell and T-cell prolymphocytic leukemias, response rates as high as 76% have been reported. [8] [9] [10] Other malignancies that express CD52 are potential targets for alemtuzumab therapy, including acute lymphocytic leukemia (ALL), hairy cell leukemia, and Waldenstro¨m's macroglobulinemia.
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Within the setting of allogeneic stem cell transplantation (ASCT) for hematologic malignancies, alemtuzumab has been used extensively, both in vivo and ex vivo, to deplete T cells in the graft and in the recipient, a simple procedure that is effective in controlling graft-versus-host disease (GVHD), one of the major causes of post transplant morbidity and mortality. [12] [13] [14] [15] More recently, alemtuzumab, at a total dose of 100 mg, has been used as a component of conditioning therapy prior to ASCT, a setting in which it continues to show substantial benefits in controlling GVHD. [16] [17] [18] [19] These benefits have been associated, however, with an increased risk of relapse, especially in patients with aggressive diseases such as acute leukemia, multiple myeloma, and high-grade lymphomas. This increased risk of relapse has been attributed to the persistence of antibody at the time of stem cell infusion at levels that can induce T-cell depletion in the allograft and a subsequent decrease in the graft-versusmalignancy effect. 18 In this study, we evaluated a low-dose alemtuzumab regimen for its effectiveness in minimizing toxicity and acute GVHD following high-dose cyclophosphamide, total body irradiation (TBI), and ASCT as conditioning in the treatment of CD52-positive malignancies. Serum alemtuzumab levels were determined both before and after transplantation to see whether these patients had residual antibody levels with the lower dose, or to see whether this had an effect on outcome.
Patients and methods

Patients
Only patients with a diagnosis of advanced/refractory hematologic malignancy with a level of CD52 expression of 420% were included in the study. The other inclusion criteria were age o65 years; ECOG performance status p2; and a human leukocyte antigen-identical or oneantigen-mismatched sibling or a matched unrelated donor (MUD). Patients were excluded if they had received prior chemotherapy within the previous 4 weeks; were pregnant or lactating; had severe concomitant psychiatric illness; tested positive for HIV, HTLV-1 or hepatitis; or showed diminished renal function (serum creatinine 41.6 mg/dl), serum bilirubin 41.5 mg/dl, pulmonary function (lung diffusion capacity o50%), or cardiac function (ejection fraction o50% of the predicted value).
In all, 12 patients with advanced ALL (n ¼ 9) or CLL in transformation to Richter's syndrome (n ¼ 3) were treated. Patient characteristics are shown in Table 1 . The disease was chemosensitive in 67% of patients, but was refractory or in untreated relapse in 33% of patients. Two patients were treated in first complete response (CR). One had Philadelphia chromosome-positive ALL, and the other had ALL with multiple, complex chromosomal abnormalities. One patient was in relapse after autologous stem cell transplantation. Nine transplants were from a sibling or related donor, and three were from a MUD. Two patients received bone marrow stem cells, while 10 received mobilized peripheral blood stem cells.
Treatment
Patients received low-dose alemtuzumab 10 mg intravenously (i.v.) daily on days À7 to À3 in combination with high-dose cyclophosphamide 60 mg/kg daily i.v. on days À7 and À6 and TBI (days À4 to À1; 12 Gy over four fractions) (Figure 1 ). Premedication to avoid infusionrelated reactions to alemtuzumab consisted of hydrocortisone 150 mg i.v., diphenhydramine 25 mg i.v., and acetaminophen 650 mg p.o., given 30 min prior to the start of the infusion.
GVHD prophylaxis consisted of tacrolimus 0.015 mg/kg daily from day À2 (dose adjusted to maintain a trough level of 5-15 ng/ml) and methotrexate 5 mg/m 2 on days 1, 3, and 6. In MUD transplants, methotrexate was also given on day 11. Tacrolimus was maintained for 6 months (9 if MUD) and then tapered.
Patients received valganciclovir 900 mg twice daily p.o. on days À7 to À2 as cytomegalovirus (CMV) prophylaxis. On day À1, valganciclovir was replaced with foscarnet 60 mg/kg/daily i.v. until neutrophil engraftment, at which point foscarnet was stopped and valganciclovir was resumed.
Patients received i.v. immunoglobulin 200 mg/kg/weekly until day 90 as anti-infective prophylaxis. Levofloxacin 500 mg and fluconazole 200 mg were administered daily for bacterial and fungal prophylaxis, respectively.
Evaluations
Bone marrow aspirates and biopsies were obtained at 1, 3, and 6 months after transplant, and every 6 months thereafter. Computed tomographic scans of the chest, abdomen, and pelvis were undertaken at the same time intervals for patients with CLL/Richter's syndrome. Chimeric studies from peripheral blood were performed by polymerase chain reaction at the time of engraftment and at the time of disease evaluation.
Alemtuzumab enzyme-linked immunosorbant assay
Serum levels of alemtuzumab were measured by the ELISA methodology developed and described by Manshouri et al. Fisher Scientific International) and blocked in a solution of 300 ml BSA (2%) in PBS-Tween 20 for 1.5 h at 371C. Plates were then washed six times with PBS-Tween 20, and 100 ml of a 1:20 000 dilution of each patient sample in 2% BSA-PBS was added in duplicate. Plates were incubated for 1.2 h at room temperature with slow shaking, after which they were washed at least eight times with PBS-Tween 20 and incubated with 100 ml of a 1:50 000 dilution of peroxidase-conjugated affinity-purified rabbit anti-human-Fc in PBS-Tween 20 containing 15% fetal calf serum for 1.5 h at room temperature with constant shaking. After another eight washes with PBS-Tween 20, 100 ml of substrate (3,3 0 -5,5 0 -tetramethylbenzidine; DAKO, Carpinteria, CA, USA) was added to each well. After 4-8 min, the reaction was stopped with 50 ml of 2 N HCl; plates were read at 450 nm, and a log reading of samples against control was calculated. The sensitivity level of the test was 0.5 mm/ml.
Results
Engraftment
All patients engrafted rapidly; the median time to an absolute neutrophil count 40.5 Â 10 9 /l was 14 days (range 11-17 days), and the median time to a platelet count 420 Â 10 9 /l was 16 days (range 6-30 days). By 1 month after transplant, nine patients had 100% donor chimerism while three had mixed donor chimerism. At 3 months, 11 patients had 100% donor chimerism, with the 12th had mixed chimerism. At 12 months, five patients were tested; four had 100% and one had 90% donor cells.
Efficacy
Nine patients achieved CR and one achieved partial response (PR) after transplant ( Table 2) . Overall survival and disease-free survival curves are shown in Figure 2 . At a median follow-up interval of 14.7 months (range 3-23.5 months), seven patients remained alive, five free of disease and in CR at 4, 15, 18, 19, and 24 months. Four patients died of disease progression at 5, 6, 7, and 8 months after transplant. One patient died of infection.
Safety
No patient experienced moderately severe or severe acute GVHD. One patient developed a grade I skin reaction and another, grade II GVHD of the gastrointestinal tract.
Two of the 11 evaluable patients (18%) had extensive chronic GVHD. Two other patients experienced limited chronic GVHD.
CMV reactivation occurred in three patients, none of whom developed CMV disease. All reactivations occurred early, during the first 45 days after transplant. A total of six patients developed bacterial infection (one catheter related, four in blood, and one in urine). Four patients developed polyoma virus-positive hemorrhagic cystitis. One patient Low-dose alemtuzumab in allogeneic transplantation IF Khouri et al had influenza and one had nasopharangeal herpes simplex reactivation. One patient had a Fusarium infection localized to the skin, and two patients developed Candida infections (one in blood and one in sputum). All these infections all responded to anti-infective therapy. One patient died of disseminated Aspergillus infection, which may have been present prior to treatment.
Serum levels of alemtuzumab
Antibody levels were measured to establish whether there was residual alemtuzumab at the time of transplant that might contribute to depletion of donor T cells. In all, 11 patients had the antibody level tested 1 day prior to infusion of the bone marrow or peripheral blood stem cells. A total of 25 additional samples were tested sequentially up to 21 days after transplantation. Alemtuzumab was not detected in any of the samples tested, including the pretransplant ones. Positive and negative controls were run simultaneously and were adequate.
Discussion
Mortality and morbidity related to GVHD remains a significant cause of post transplant complications and death. In an attempt to counter this, alemtuzumab has been incorporated into the conditioning regimen.
The dose and schedule of alemtuzumab that are necessary to achieve those goals are subject to investigation. In published reports, a dose of 100 mg divided over 5 days, with the last dose given 4 days prior to ASCT, has predominated; alemtuzumab levels were detected in the serum for several days after transplantation. In a study by Morris et al, 21 the median level at 28 days was 1.0 mg/ml. The limit of serum quantitation by the methodology used in that study was similar to the one in our report (0.5 mg/ml), and seven of 10 patients had a level above that threshold at 28 days after transplantation. The authors also reported that the half-life from 4 to 32 days after the last infusion was 8 days, giving an estimated time to achieve levels below 0.1 mg/ml of 60 days. This strategy resulted in a significant reduction of GVHD, but also an increased risk of relapse in patients with aggressive malignancies. 22 In this study, we investigated the use of low-dose alemtuzumab (50 mg divided over 5 days), in combination with high-dose cyclophosphamide and TBI for patients with CD52-positive ALL or CLL/Richter's syndrome. Unlike other reported studies, our protocol employed a standard GVHD prophylaxis with tacrolimus for 6 months and low-dose methotrexate rather than cyclosporin for 3 months. With this strategy, no patients in our study had acute GVHD more severe than grade II. This represents an improvement in risk compared to that experienced by an historical group of patients with ALL (median age 32 years), who underwent ASCT at our institution with tacrolimus/methotrexate, but without alemtuzumab as prophylaxis for GVHD. 23 The actuarial risks of acute grade II-IV and III-IV GVHD in those patients were 30 and 15%, respectively. The 3-year disease-free survival rates in this historical control group were 30% for patients transplanted in second remission and 8% for those who were in relapse at the time of transplant.
Five of 12 patients in this study remained alive and in remission at a median follow-up time of 14.7 months. Alemtuzumab was not detected in these patients at the time of stem cell infusion. This absence of measurable antibody is probably related to its active binding to CD 52-positive receptors, which were strongly expressed by the treated malignancies. Thus, donor T cells and dendritic cells were not be depleted, enhancing the killing effect of GVL, while the low incidence of acute GVHD may be explained by the depletion of host dendritic cells by alemtuzumab. These cells have been demonstrated to express CD52 and act as antigen-presenting cells. 24, 25 The preliminary results presented have demonstrated the success of a low 50 mg dose of alemtuzumab in a high-dose therapy setting, increasing the potential for treatment of more aggressive CD52-positive leukemias and lymphomas, without acute GVHD-related post transplant complications. Our results also emphasize the need for further studies to determine the optimal dose and schedule of alemtuzumab. Different regimens may be indicated for CD52-positive and -negative malignancies.
